Melbourn has over 20 years of experience in analytical testing and formulation for inhaled products and its reputation for providing outstanding and responsive customer service, along with its specialist skills, complement Intertek’s existing technical capabilities and culture.
Intertek has a network of more than 1000 laboratories and offices and over 35,000 people in more than 100 countries.
Mark Hammond, CEO, Melbourn Scientific, adds: “We are delighted that Melbourn is now under the umbrella of Intertek. It will allow us to offer a wider range of services to our existing customers as well as introduce our specialist expertise to Intertek’s impressive network of clients. The move will also greatly enhance the career development and progression opportunities for our staff."
Dr Andrew Swift, SVP, Intertek Chemicals and Pharmaceuticals, says: "Combining Intertek's GMP/GLP pharmaceutical studies and our advanced capabilities for measuring device/drug interaction with Melbourn's expertise in OINDP drug characterisation provides a unique and compelling offering to clients. Adding in our global reach and Regulatory Services, Intertek now offers a comprehensive and global end-to-end expert service to support drug development which is unmatched by current competitors."
______________________________________________